NYSE:CVD Covance (CVD) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free CVD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Covance alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Covance Stock (NYSE:CVD)Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). CVD Stock News HeadlinesFebruary 23, 2024 | msn.comNew study shows glycan sugar coating of IgG immunoglobulin can predict cardiovascular healthJanuary 26, 2024 | msn.comClinical study supports the long-lasting impacts of typhoid conjugate vaccineApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.October 8, 2023 | msn.com“Unblocked” movement to tackle burden of cardiovascular diseasesOctober 6, 2023 | reuters.comAntidumping separate rate process and pitfalls importers should considerSeptember 24, 2023 | investing.comCVD Historical DataAugust 26, 2023 | msn.comFeeling safe from crime ‘reduces heart attack risk’July 27, 2023 | finance.yahoo.comCVV - CVD Equipment CorporationApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.May 22, 2023 | benzinga.comHolter ECG Market is Expected to Reach $558 million | MarketsandMarkets.May 8, 2023 | technews.tmcnet.comUCARDIA ANNOUNCES ACQUISITION OF PHAS3; LAUNCHES CARDIOLOGIST PRACTICE REMOTE PATIENT MONITORING OFFERINGJuly 21, 2022 | marketwatch.comAnalgesics Market 2022 Size, Demand, Outlook, Trends, Revenue, Future Growth Opportunities till 2030May 10, 2022 | finance.yahoo.comPeople Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular CareMay 4, 2022 | thestreet.comCramer's 'Mad Money' Recap: Stake Out AeroVironmentMarch 14, 2022 | msn.comPeople with serious mental illness more likely to have heart disease – studyMarch 13, 2022 | msn.comPeople with serious mental illness more likely to suffer from heart disease – studyJanuary 31, 2022 | ca.finance.yahoo.com1 Top Healthcare Stock to Buy Low TodayJanuary 21, 2022 | thestreet.comCovance Stock Hits New 52-Week High (CVD)October 26, 2021 | finance.yahoo.comNovartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)September 28, 2021 | msn.comWorld Heart Day 2021: Know all about the date, history, significance and themeSee More Headlines Receive CVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Covance and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/04/2015Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CVD CUSIP22281610 CIK1023131 Webwww.covance.com Phone+1-609-4524440FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report CVD Stock Analysis - Frequently Asked Questions How were Covance's earnings last quarter? Covance Inc (NYSE:CVD) issued its earnings results on Wednesday, February, 4th. The healthcare company reported $0.97 earnings per share for the quarter, hitting the consensus estimate of $0.97. The healthcare company earned $634 million during the quarter, compared to analysts' expectations of $631.30 million. What other stocks do shareholders of Covance own? Based on aggregate information from My MarketBeat watchlists, some companies that other Covance investors own include Allena Pharmaceuticals (ALNA), Laboratory Co. of America (LH), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB), Asterias Biotherapeutics (AST), Catalyst Biosciences (CBIO), Crestwood Equity Partners (CEQP), Cisco Systems (CSCO), Fate Therapeutics (FATE) and Flexion Therapeutics (FLXN). This page (NYSE:CVD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Covance Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
